Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02556346
Recruitment Status : Withdrawn (The patient population (CLL & SLL) was included in another ongoing study involving NHL patients.)
First Posted : September 22, 2015
Last Update Posted : March 2, 2016
Sponsor:
Information provided by (Responsible Party):
Molecular Templates, Inc.

Brief Summary:
This Phase I, multiple ascending dose study will seek to enroll subjects with relapsed/refractory Chronic B-cell Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with confirmed and measurable disease who have received standard treatment with at least one anti-CD20 antibody (e.g.; rituximab, ofatumumab) containing front-line regimen that resulted in initial response, followed by relapse/recurrence and who are not eligible for any further approved biologic therapy, chemotherapy and/or autologous stem transplantation and/or refuse alternative approved therapies and/or are unlikely to achieve clinical benefit from any therapy of higher priority by Investigator assessment.

Condition or disease Intervention/treatment Phase
Chronic B-cell Lymphocytic Leukemia Small Lymphocytic Leukemia Drug: MT-3724 Phase 1

Detailed Description:

This study is intended to provide investigators and sponsor with the following information regarding the investigational new drug MT-3724 in patients with relapsed/refractory Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma:

The maximum dose of a single course of MT-3724 given as intravenous (IV) infusions on Days 1, 3, 5, 8, 10 and 12 at which there are negligible side effects and/or at which maximum serum levels and/or at which maximum effect on blood lymphocytes are observed. Four dose levels will be investigated.

The changes in MT-3724 serum levels and blood lymphocytes over time following IV doses at different points in the study.

The changes and kinds of clinical and laboratory effects and side effects that may occur over repeated courses of MT-3724 The changes in each subject's immune status and their CLL or SLL following one or more cycles of 6 infusions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study Start Date : November 2015
Estimated Primary Completion Date : August 2016
Estimated Study Completion Date : December 2016


Arm Intervention/treatment
Experimental: MT-3724 Phase 1 5 mcg/kg/dose
MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 10 mcg/kg/dose
MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 20 mcg/kg/dose
MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1 50 mcg/kg/dose
MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
Drug: MT-3724
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.

Experimental: MT-3724 Phase 1b
MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
Drug: MT-3724
Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.




Primary Outcome Measures :
  1. Tolerability as measured by number of subjects with dose limiting toxicities [ Time Frame: 28 days ]
    Evaluation of tolerability of MT-3724 measured by number of subjects with dose limiting toxicities (DLTs)

  2. Safety as measured by number of subjects with Adverse Events using CTCAE [ Time Frame: 28 days and then every 6 months for up to 24 months following first dose if subject does not continue into Phase Ib ]
    Safety measured by number of subjects with Adverse Events using CTCAE Version 4.03

  3. Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters [ Time Frame: 2-3 weeks following last dose and then every 6 months for up to 24 months following first dose ]
    Evaluation of tolerability of MT-3724 given for up to 4 additional cycles measured by number, nature and severity of Adverse Events using CTCAE Version 4.03


Secondary Outcome Measures :
  1. PK as measured by concentrations of free MT-3724 (Cmax, Cinf) [ Time Frame: Days 1, 5, 8, 12, 23, and 28 ]
    Evaluation of the pharmacokinetic profile of MT-3724

  2. PK as measured by area under the curve of free MT-3724 (AUC) [ Time Frame: Days 1, 5, 8, 12, 23, and 28 ]
    Evaluation of the pharmacokinetic profile of MT-3724

  3. PK as measured by time to maximum concentration of free MT-3724 ( tmax) [ Time Frame: Days 1, 5, 8, 12, 23, and 28 ]
    Evaluation of the pharmacokinetic profile of MT-3724

  4. PD as measured by immunogenicity (anti-drug antibodies) [ Time Frame: During Screening, Days 23-25, Day 1 of cycle 2, and at final end of study visit ]
    Evaluation of the pharmacodynamic profile of MT-3724

  5. Tumor Response as measured by PET or CT scan [ Time Frame: During Screening, Days 43 & 86 ]
    Evaluation of tumor response using International Working Group Response Criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women, age 18 years or older
  • Life expectancy > 3 months
  • Flow cytometric confirmation of CLL is required at screening. Previous confirmation of CLL/SLL including confirmed immunohistological diagnosis with a characteristic CD5+/CD20+ B-cell immunophenotype according to WHO criteria
  • For CLL: a. An absolute peripheral blood monoclonal CD20+/CD5+ B-lymphocyte count > 5000/μL for the duration of at least 3 months
  • For SLL: An absolute peripheral blood monoclonal CD20+/CD5+ B-lymphocyte count < 5000/μL AND Presence of lymphadenopathy and/or splenomegaly, with histopathological evaluation of a lymph node biopsy consistent with CLL/SLL.
  • Staging CLL: Rai Stage III or IV disease, or stage 0-II disease that meets NCIWG criteria for active disease requiring therapy; SLL: Intermediate or high risk by Ann Arbor Staging with Cotswald Modifications that meets criteria for active disease requiring therapy.
  • Relapsed/ Refractory CLL/SLL that has progressed despite treatment with all approved therapies known to provide clinical benefit for their disease and for which the potential subject is eligible or the potential subject must have refused any other available approved treatment options prior to consideration for enrollment.
  • Potential subjects must have received at least one anti-CD20 antibody containing regimen in the past that resulted in initial measurable response (partial or complete remission), followed by relapse/recurrence.
  • Potential subjects for which high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) is considered a standard curative therapy are eligible for this study if the potential subject's disease has relapsed after HD-ASCT, or the potential subject is not eligible for HD-ASCT or the potential subject has refused HD-ASCT.
  • Potential subjects who have had HD-ASCT must be at least 26 weeks beyond transplant.
  • All potential subjects are required to have measurable disease following previous therapy for CLL/SLL. Measurable disease, as determined by NCI-WG criteria, following standard first-line or salvage therapy; this includes potential subjects with progressive disease (PDs), stable disease (SDs), or partial remission (PR) and/or Residual disease as determined by measurable disease (i.e., PDs, SDs, or PR) or by MRD positivity, determined by flow cytometry of bone marrow and/or peripheral blood (see Laboratory Manual) in potential subjects with Complete Response (CR) or CR with incomplete bone marrow recovery (CRi) (previously termed "nodular partial remission" [(nPR])
  • Eastern Cooperative Oncology Group (ECOG) performance status of < 2.
  • Patients must be at least 28 days past their last course of leukemia or lymphoma treatment and have recovered from side effects of such therapy completely or with only minor residual symptoms including any significant laboratory. Patients with pre-existing severe or life threatening side effects/conditions from prior therapy or due to other diseases may not be enrolled
  • Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods while on study therapy and for 12 week following their last dose of study medication.

Exclusion Criteria:

  • Ongoing use of any approved or investigational anti-neoplastic therapies with the exceptions of ongoing hormonal therapy for breast cancer (without evidence of active disease) or prostate cancer (stable on hormonal therapy).
  • History of an absolute anti-CD20 monoclonal antibody (MAb) refractory CLL/SLL, defined as a failure to have ever achieved a PR, CR with persistent lymphocytic nodules in the marrow ("nPR"), or CR for at least 6 months in response to at least one anti-CD20 MAb-containing regimen amongst all past CLL/SLL treatments.
  • Potential subjects cannot have experienced a significant (CTCAE Grade 3 or 4 with or without neutropenia) infection within 2 weeks of the first dose of MT-3724.
  • Patients who cannot comply with protocol requirements including clinic visits for intravenous infusions and birth control measures may not be enrolled.
  • Female patients who are pregnant or are breast feeding.
  • Patients are not eligible if they are using any other approved or investigational anti-neoplastic therapies or any other investigational therapies for any other reason.
  • Patients may not be receiving systemic corticosteroid therapy at a prednisone dose > 20 mg/day (or steroid equivalent) within 2 weeks of starting study.
  • Patients with uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to start of study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis may not be enrolled.
  • Patients with a known history of drug abuse or any chronic neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic or renal disease (including a history of hemolytic uremic syndrome) that in the opinion of the Investigator would adversely affect study participation.
  • Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
  • Patients must not have received any vaccines for 28 days prior to administration of their first dose of MT-3724 and should not receive any vaccine during the study or within 28 days after their last dose of MT-3724.
  • Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are not eligible.
  • Potential subjects who have undergone allogeneic hematopoietic stem cell transplant or any solid organ transplant.
  • Autologous hematopoietic stem cell transplant within 26 weeks prior to study entry; any history of allogeneic hematopoietic stem cell transplant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02556346


Sponsors and Collaborators
Molecular Templates, Inc.
Investigators
Layout table for investigator information
Study Director: David Valacer, MD Molecular Templates
Layout table for additonal information
Responsible Party: Molecular Templates, Inc.
ClinicalTrials.gov Identifier: NCT02556346    
Other Study ID Numbers: MT-3724_CLL_SLL_001
First Posted: September 22, 2015    Key Record Dates
Last Update Posted: March 2, 2016
Last Verified: February 2016
Keywords provided by Molecular Templates, Inc.:
CD20
immunotoxin
CLL
SLL
leukemia
lymphocytic lymphoma
lymphocytic leukemia
MT-3724
relapsed
refractory
immunotherapy
cancer
antibodies
safety
pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases